136 related articles for article (PubMed ID: 26792509)
1. [Health economic evaluation of human papillomavirus vaccines in the developing countries: systematic reviews].
Song X; Mao F; Zhou Z; Zhao Q; Fang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jan; 50(1):85-90. PubMed ID: 26792509
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
3. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
4. Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review.
Ekwunife OI; Grote AG; Mosch C; O'Mahony JF; Lhachimi SK
Syst Rev; 2015 May; 4():68. PubMed ID: 25963745
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
7. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
Van Minh H; My NTT; Jit M
BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
[TBL] [Abstract][Full Text] [Related]
9. Cost and financing issues limit access to the HPV vaccine.
Muthumariappan M; Raj GA
Asian Pac J Cancer Prev; 2010; 11(2):573-4. PubMed ID: 20843155
[TBL] [Abstract][Full Text] [Related]
10. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
11. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
12. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
13. The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review.
Setiawan D; Oktora MP; Hutubessy R; Riewpaiboon A; Postma MJ
Expert Rev Vaccines; 2017 Sep; 16(9):933-943. PubMed ID: 28730914
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.
Fesenfeld M; Hutubessy R; Jit M
Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973
[TBL] [Abstract][Full Text] [Related]
18. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
Moss JL; Reiter PL; Brewer NT
Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
[TBL] [Abstract][Full Text] [Related]
19. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.
Ekwunife OI; O'Mahony JF; Gerber Grote A; Mosch C; Paeck T; Lhachimi SK
Pharmacoeconomics; 2017 Jan; 35(1):65-82. PubMed ID: 27637758
[TBL] [Abstract][Full Text] [Related]
20. Controlling cervical cancer.
Bonati M; Garattini S
Pharmacoeconomics; 2009; 27(2):91-3. PubMed ID: 19254043
[No Abstract] [Full Text] [Related]
[Next] [New Search]